ClinicalTrials.Veeva

Menu
P

Penn State Health Milton S. Hershey Medical Center | Neuro-Oncology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

CC-93538
Temozolomide
Patidegib
Gemcitabine
STAR-0215
Cannabidiol
Reldesemtiv
Mavacamten
Cilofexor
Bexotegrast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

25 of 78 total trials

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in s...

Active, not recruiting
Sickle Cell Disease
Other: Mitapivat-matching placebo
Drug: Mitapivat
Locations recently updated

This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followe...

Enrolling
Bladder Cancer
Urologic Cancer
Other: n-dodecyl-B-D-maltoside
Drug: Cretostimogene Grenadenorepvec

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Active, not recruiting
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1...

Active, not recruiting
Hereditary Angioedema
Drug: STAR-0215

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Sub...

Active, not recruiting
Inclusion Body Myositis
Drug: ABC008

A prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System, with 2:1 study vs. active concurrent control group allocati...

Active, not recruiting
Ventricular Dysfunction, Left
Device: Revivent TC

This is a non-randomized, prospective, multi-center Early Feasibility Study to evaluate the AccuCinch® Ventricular Restoration System in Patients wit...

Active, not recruiting
Cardiomyopathy, Dilated
Heart Failure
Device: AccuCinch® Ventricular Restoration

The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Ther...

Active, not recruiting
Arrhythmia, Ventricular
Tachycardia, Ventricular
Device: mCRM Therapy System

The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.

Active, not recruiting
Heart Failure
Device: Investigational LUX-Dx ICM Implant

This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and tolerable. Exploratory objectives include whether BX004-A...

Active, not recruiting
Cystic Fibrosis
Chronic Pseudomonas Aeruginosa Infection
Drug: BX004-A
Drug: Placebo

This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed...

Enrolling
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Non-Hodgkin Lymphoma
Drug: NKTR-255 at 3.0 μg/kg
Drug: NKTR-255 at 3.0/6.0 μg/kg

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with adva...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: Cetuximab
Drug: Afatinib

This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV D...

Enrolling
Arteriovenous Fistula
Device: LUTONIX 035 Drug Coated Balloon PTA Catheter

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment o...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: PLN-74809
Drug: Placebo

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling
Primary Biliary Cirrhosis
Drug: Seladelpar 10 mg Capsule
Drug: Seladelpar 5 mg Capsule

To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

Enrolling
Primary Biliary Cholangitis
Drug: Seladelpar
Drug: Placebo

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen e...

Invitation-only
Acute Myocardial Infarction
Combination Product: Placebo
Combination Product: Selatogrel

The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the...

Enrolling
Glioblastoma
Recurrent Glioblastoma
Device: SonoCloud-9 (SC9)
Drug: Temozolomide

Phase 2 study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD emphysema

Enrolling
Emphysema
Alpha 1-Antitrypsin Deficiency
Drug: Zemaira
Drug: INBRX-101

Trial sponsors

Penn State Health logo
A
Bristol-Myers Squibb (BMS) logo
Gilead Sciences logo
Takeda logo
B
Boston Scientific logo
C
Celgene logo
Children's Hospital of Philadelphia (CHOP) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems